MX2020005736A - Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. - Google Patents

Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Info

Publication number
MX2020005736A
MX2020005736A MX2020005736A MX2020005736A MX2020005736A MX 2020005736 A MX2020005736 A MX 2020005736A MX 2020005736 A MX2020005736 A MX 2020005736A MX 2020005736 A MX2020005736 A MX 2020005736A MX 2020005736 A MX2020005736 A MX 2020005736A
Authority
MX
Mexico
Prior art keywords
glutarimide derivatives
general formula
methods
producing
derivatives
Prior art date
Application number
MX2020005736A
Other languages
English (en)
Other versions
MX383551B (es
Inventor
Vladimir Evgenievich Nebolsin
Tatyana Alexandrovna Kromova
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2013116826A external-priority patent/RU2562773C3/ru
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises
Publication of MX2020005736A publication Critical patent/MX2020005736A/es
Publication of MX383551B publication Critical patent/MX383551B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se relaciona con derivados de glutarimida biológicamente activos novedosos de formula general (I) o sales farmaceuticamente aceptables de los mismos, el uso de los mismos como agentes para tratar enfermedades del tracto respiratorio superior, composiciones farmaceuticas que contienen derivados de glutarimida de formula general (I) y metodos para producir derivados de glutarimida de formula general (I) calentando una monoamida de ácido dicarboxilico de formula general (II) con un agente deshidratante.
MX2020005736A 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida MX383551B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013116826A RU2562773C3 (ru) 2013-04-12 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
PCT/RU2014/000264 WO2014168522A1 (ru) 2013-04-12 2014-04-10 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Publications (2)

Publication Number Publication Date
MX2020005736A true MX2020005736A (es) 2021-06-14
MX383551B MX383551B (es) 2025-03-14

Family

ID=51689819

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015014336A MX380619B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
MX2020005736A MX383551B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
MX2020005735A MX383762B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
MX2020005738A MX385329B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015014336A MX380619B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020005735A MX383762B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
MX2020005738A MX385329B (es) 2013-04-12 2014-04-10 Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida

Country Status (16)

Country Link
US (8) US9815814B2 (es)
EP (3) EP3722290B1 (es)
JP (4) JP6529958B2 (es)
KR (3) KR102296182B1 (es)
CN (4) CN110229140B (es)
AU (5) AU2014251442A1 (es)
BR (3) BR122020010210B1 (es)
CA (1) CA2909057C (es)
EA (4) EA032951B1 (es)
ES (1) ES2988541T3 (es)
IL (4) IL266301B2 (es)
MX (4) MX380619B (es)
SG (4) SG10201802650WA (es)
UA (1) UA121299C2 (es)
WO (1) WO2014168522A1 (es)
ZA (3) ZA201508278B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
GEAP202115467A (en) 2017-09-07 2021-10-11 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
WO2020089844A1 (en) * 2018-11-01 2020-05-07 Ahammune Biosciences Private Limited Novel imidazole compounds, process for the synthesis and uses thereof
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
TN2022000350A1 (en) * 2020-06-26 2024-07-04 Ltd “Valenta Intellekt” Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity
WO2023121519A1 (ru) * 2021-12-23 2023-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-диона для лечения covid-19
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение
WO2023249516A1 (ru) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новая кристаллическая форма 1-[2-(1-метилимидазол-4-ил)этил]пергидроазин-2,6-диона и ее фармацевтическое применение
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081308A (en) * 1959-12-29 1963-03-12 Searle & Co 5-carbocyclic-3-imidomethyloxazolidines and process
US3171839A (en) * 1961-05-18 1965-03-02 Searle & Co 4-alkyl-1-(cyclic imidoalkyl) piperidines
GB1033251A (en) * 1961-09-07 1966-06-22 Distillers Co Yeast Ltd Glutarimide derivatives
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPS606686A (ja) * 1983-06-27 1985-01-14 Kissei Pharmaceut Co Ltd チオフエン誘導体及びその製造方法
JPS6066686A (ja) 1983-09-19 1985-04-16 Toshiba Corp ライン駆動電動機の速度制御装置
SE8600261D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Indolokinoxaliner med substituenter i 6-position som innehaller cykliska grupper
SU1836365A3 (ru) * 1991-01-24 1993-08-23 Физиko-Xиmичeckий Иhctиtуt Иm.A.B.Бoгatckoгo;Hии@ Фapmakoлoгии Poccийckoй Amh Способ получения ν-0-пиперазинил)бутилглутаримидов
FR2737725B1 (fr) 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
EP1020447A4 (en) * 1997-09-11 2000-11-15 Nissan Chemical Ind Ltd PYRAZOLE-BASED COMPOUNDS AND PLANT DISEASE CONTROL AGENT
ITMI991578A1 (it) * 1999-07-15 2001-01-15 Recordati Ind Chimica E Farma Amidi e imidi cicliche dotate di attivita' antagonista selettiva per il recettore adrenergico
US6413428B1 (en) 1999-09-16 2002-07-02 Berger Instruments, Inc. Apparatus and method for preparative supercritical fluid chromatography
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CA2526204A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
CN1260218C (zh) * 2003-11-06 2006-06-21 天津药物研究院 一类pdf酶抑制剂－异羟肟酸系列化合物及其合成方法与用途
WO2006040646A1 (en) * 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
BRPI0607062A2 (pt) * 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
WO2010033340A1 (en) * 2008-09-16 2010-03-25 The Trustees Of The University Of Pennsylvania Influenza a virus inhibition
SG184430A1 (en) * 2010-04-15 2012-11-29 Biota Scient Management Compound for treatment of respiratory condition or disease
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
US20120157382A1 (en) * 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
EP3722290B1 (en) 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Also Published As

Publication number Publication date
AU2018236805B2 (en) 2020-04-09
EA201792597A3 (ru) 2018-09-28
JP2019034964A (ja) 2019-03-07
EA201792072A3 (ru) 2018-09-28
KR20200069381A (ko) 2020-06-16
RU2013116826A (ru) 2014-10-20
AU2020203630B2 (en) 2021-04-22
CN106061962A (zh) 2016-10-26
UA121299C2 (uk) 2020-05-12
MX383762B (es) 2025-03-14
US10377739B2 (en) 2019-08-13
CN110229140A (zh) 2019-09-13
KR20160021092A (ko) 2016-02-24
KR20200069380A (ko) 2020-06-16
AU2020203632A1 (en) 2020-06-25
MX2015014336A (es) 2016-06-07
MX385329B (es) 2025-03-18
US10155743B2 (en) 2018-12-18
US10155745B2 (en) 2018-12-18
IL266301B2 (en) 2023-03-01
US20190084961A1 (en) 2019-03-21
EA032951B1 (ru) 2019-08-30
AU2018236805C1 (en) 2020-11-05
ZA201603108B (en) 2017-08-30
CA2909057A1 (en) 2014-10-16
BR122020010210B1 (pt) 2022-09-20
WO2014168522A9 (ru) 2014-12-04
IL266301A (en) 2019-06-30
US9815814B2 (en) 2017-11-14
SG10201802648SA (en) 2018-05-30
IL241998B (en) 2019-06-30
US20180016253A1 (en) 2018-01-18
EP2985282A4 (en) 2017-02-22
WO2014168522A1 (ru) 2014-10-16
JP6843103B2 (ja) 2021-03-17
EP3722290A1 (en) 2020-10-14
AU2020203630A1 (en) 2020-06-25
ZA201603109B (en) 2017-08-30
RU2562773C2 (ru) 2015-09-10
MX380619B (es) 2025-03-12
KR102254315B1 (ko) 2021-05-25
BR112015025804A2 (pt) 2017-07-25
JP6529958B2 (ja) 2019-06-12
AU2020203632B2 (en) 2021-04-22
MX2020005735A (es) 2021-06-21
SG10201802650WA (en) 2018-05-30
SG10201802647QA (en) 2018-05-30
CA2909057C (en) 2022-03-22
CN110128406A (zh) 2019-08-16
JP6620324B2 (ja) 2019-12-18
US20180016257A1 (en) 2018-01-18
CN110172055A (zh) 2019-08-27
CN110229140B (zh) 2022-06-10
JP2016516766A (ja) 2016-06-09
EP2985282A1 (en) 2016-02-17
KR102255929B1 (ko) 2021-05-26
ZA201508278B (en) 2017-11-29
EA201792071A3 (ru) 2018-09-28
AU2018236805A1 (en) 2018-10-18
MX383551B (es) 2025-03-14
BR112015025804B1 (pt) 2022-01-04
US10155747B2 (en) 2018-12-18
JP2019034965A (ja) 2019-03-07
EA032938B1 (ru) 2019-08-30
CN106061962B (zh) 2019-09-06
EA033054B1 (ru) 2019-08-30
US20180016256A1 (en) 2018-01-18
IL266302B (en) 2021-09-30
IL266300A (en) 2019-06-30
AU2014251442A1 (en) 2015-12-03
AU2020203968B2 (en) 2021-04-22
CN110128406B (zh) 2021-08-27
JP6627039B2 (ja) 2020-01-08
JP2019034966A (ja) 2019-03-07
US10155746B2 (en) 2018-12-18
US20180022728A1 (en) 2018-01-25
US20160046598A1 (en) 2016-02-18
IL266300B (en) 2021-10-31
EP3722290B1 (en) 2023-06-21
WO2014168522A4 (ru) 2015-01-22
CN110172055B (zh) 2021-10-29
MX2020005738A (es) 2021-08-13
US20180016255A1 (en) 2018-01-18
ES2988541T3 (es) 2024-11-20
US20180016254A1 (en) 2018-01-18
IL266302A (en) 2019-06-30
AU2020203968A1 (en) 2020-07-02
IL266301B (en) 2022-11-01
US10196377B2 (en) 2019-02-05
EA201792597A2 (ru) 2018-04-30
EP3725785C0 (en) 2024-04-10
US10155744B2 (en) 2018-12-18
EA201792071A2 (ru) 2018-04-30
BR122020010204B1 (pt) 2022-03-03
EP3725785A1 (en) 2020-10-21
SG11201508394UA (en) 2015-11-27
EA201591957A1 (ru) 2016-02-29
EA201792072A2 (ru) 2018-04-30
EA031392B1 (ru) 2018-12-28
EP3725785B1 (en) 2024-04-10
KR102296182B1 (ko) 2021-09-02

Similar Documents

Publication Publication Date Title
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
DOP2017000034A (es) Compuestos de imidazopiridazina
BR112017000584A2 (pt) inibidores da aldosterona sintase
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
BR112015004523A2 (pt) compostos de tetraciclina
UY35323A (es) Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo
BR112015004292A2 (pt) compostos do tipo indol-amida como inibidores de beta-amiloide
TH129186A (th) สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors)